GB2304047A - Pharmaceutical compositions containing cytokines - Google Patents

Pharmaceutical compositions containing cytokines Download PDF

Info

Publication number
GB2304047A
GB2304047A GB9516287A GB9516287A GB2304047A GB 2304047 A GB2304047 A GB 2304047A GB 9516287 A GB9516287 A GB 9516287A GB 9516287 A GB9516287 A GB 9516287A GB 2304047 A GB2304047 A GB 2304047A
Authority
GB
United Kingdom
Prior art keywords
wounds
healing
composition
cytokine
promoting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB9516287A
Other languages
English (en)
Other versions
GB9516287D0 (en
Inventor
Mark William James Ferguson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Manchester
Original Assignee
Victoria University of Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Victoria University of Manchester filed Critical Victoria University of Manchester
Priority to GB9516287A priority Critical patent/GB2304047A/en
Publication of GB9516287D0 publication Critical patent/GB9516287D0/en
Priority to PCT/GB1996/001930 priority patent/WO1997005894A1/en
Priority to US09/011,027 priority patent/US6387364B1/en
Priority to EP96926507A priority patent/EP0871473B1/en
Priority to ES96926507T priority patent/ES2187665T3/es
Priority to PT96926507T priority patent/PT871473E/pt
Priority to AT96926507T priority patent/ATE229814T1/de
Priority to DK96926507T priority patent/DK0871473T3/da
Priority to ZA9606744A priority patent/ZA966744B/xx
Priority to AU66660/96A priority patent/AU719089B2/en
Priority to DE69625516T priority patent/DE69625516T2/de
Priority to JP50824697A priority patent/JP4050317B2/ja
Priority to CA2229078A priority patent/CA2229078C/en
Publication of GB2304047A publication Critical patent/GB2304047A/en
Priority to US10/082,221 priority patent/US7052684B2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Invalid Beds And Related Equipment (AREA)
  • Eye Examination Apparatus (AREA)
  • Prostheses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GB9516287A 1995-08-09 1995-08-09 Pharmaceutical compositions containing cytokines Withdrawn GB2304047A (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
GB9516287A GB2304047A (en) 1995-08-09 1995-08-09 Pharmaceutical compositions containing cytokines
CA2229078A CA2229078C (en) 1995-08-09 1996-08-08 Pharmaceutical composition containing il-10
AT96926507T ATE229814T1 (de) 1995-08-09 1996-08-08 Verwendung von il-10 zur wundheilung mit verminderter narbenbildung
ZA9606744A ZA966744B (en) 1995-08-09 1996-08-08 Pharmaceutical composition.
EP96926507A EP0871473B1 (en) 1995-08-09 1996-08-08 Use of il-10 for wound healing with reduced scarring
ES96926507T ES2187665T3 (es) 1995-08-09 1996-08-08 Uso de la il-10 para curar heridas con una cicatrizacion reducida.
PT96926507T PT871473E (pt) 1995-08-09 1996-08-08 Utilizacao de il-10 para curar feridas com cicatrizacao reduzida
PCT/GB1996/001930 WO1997005894A1 (en) 1995-08-09 1996-08-08 Pharmaceutical composition containing il-10
DK96926507T DK0871473T3 (da) 1995-08-09 1996-08-08 Anvendelse af IL-10 til sårheling med reduceret ardannelse
US09/011,027 US6387364B1 (en) 1995-08-09 1996-08-08 Methods of healing wounds and fibrotic disorders using IL-10
AU66660/96A AU719089B2 (en) 1995-08-09 1996-08-08 Pharmaceutical composition containing IL-10
DE69625516T DE69625516T2 (de) 1995-08-09 1996-08-08 Verwendung von il-10 zur wundheilung mit verminderter narbenbildung
JP50824697A JP4050317B2 (ja) 1995-08-09 1996-08-08 Ｉｌ−１０含有医薬組成物
US10/082,221 US7052684B2 (en) 1995-08-09 2002-02-26 Methods of healing wounds and fibrotic disorders using IL-10

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9516287A GB2304047A (en) 1995-08-09 1995-08-09 Pharmaceutical compositions containing cytokines

Publications (2)

Publication Number Publication Date
GB9516287D0 GB9516287D0 (en) 1995-10-11
GB2304047A true GB2304047A (en) 1997-03-12

Family

ID=10778967

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9516287A Withdrawn GB2304047A (en) 1995-08-09 1995-08-09 Pharmaceutical compositions containing cytokines

Country Status (13)

Country Link
US (2) US6387364B1 (https=)
EP (1) EP0871473B1 (https=)
JP (1) JP4050317B2 (https=)
AT (1) ATE229814T1 (https=)
AU (1) AU719089B2 (https=)
CA (1) CA2229078C (https=)
DE (1) DE69625516T2 (https=)
DK (1) DK0871473T3 (https=)
ES (1) ES2187665T3 (https=)
GB (1) GB2304047A (https=)
PT (1) PT871473E (https=)
WO (1) WO1997005894A1 (https=)
ZA (1) ZA966744B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001017558A3 (en) * 1999-09-08 2001-09-27 Schering Corp Novel uses of mammalian ccr6 receptors and related reagents

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69716460T2 (de) * 1996-12-04 2003-06-26 Renovo Ltd., Manchester Wundheilung und behandlung von fibrose
AU6045198A (en) * 1997-02-05 1998-08-25 Schering Corporation Use of il-4 and/or il-10 to treat proliferative glomerulonephritis
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
US7052686B2 (en) 2000-09-29 2006-05-30 Schering Corporation Pegylated interleukin-10
US20030148952A1 (en) * 2001-10-18 2003-08-07 Crombleholme Timothy M. Methods and materials for the recruitment of endothelial cells
NZ588743A (en) * 2003-07-15 2012-05-25 Univ Bar Ilan Use of a protein kinase C (PKC) alpha inhibitor for treating inflammation of the skin
WO2005013885A2 (en) 2003-08-07 2005-02-17 Healor Ltd. Pharmaceutical compositions and methods for accelerating wound healing
GB0500643D0 (en) 2005-01-13 2005-02-23 Renovo Ltd Medicaments
GB0524103D0 (en) 2005-11-26 2006-01-04 Medical Res Council Healing
CA2664304C (en) * 2006-09-28 2017-08-22 Schering Corporation Use of pegylated il-10 to treat cancer
AU2007319811A1 (en) 2006-11-15 2008-05-22 Coda Therapeutics, Inc. Improved methods and compositions for wound healing
CN102755649A (zh) * 2007-07-30 2012-10-31 希尔洛有限公司 药物组合物及相关方法
GB0724231D0 (en) * 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
EP2252690A2 (en) * 2007-12-21 2010-11-24 Coda Therapeutics, Inc. Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars
AU2008343840A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides, peptides or antibodies for the treatment of orthopedic conditions
CA2710386A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Improved medical devices
US20110021618A1 (en) * 2008-03-25 2011-01-27 Paloma Pharmaceuticals, Inc. Methods of treating fibrotic disorders
EP3348281B1 (en) 2008-12-17 2023-07-05 Merck Sharp & Dohme Corp. Mono- and di-peg il-10 production; and uses
CN102325789A (zh) * 2009-02-24 2012-01-18 希尔洛有限公司 用于治疗痤疮和其它病症的内脂素治疗药物
WO2012112791A1 (en) 2011-02-16 2012-08-23 Paloma Pharmaceuticals, Inc. Radiation countermeasure agents
WO2012135842A2 (en) * 2011-03-31 2012-10-04 President And Fellows Of Harvard College A unique population of regulatory t cells that regulate tissue regeneration and wound healing
CN104768567B (zh) * 2012-05-18 2017-07-11 奥塔哥创业有限公司 用于伤口愈合的联合治疗和组合物
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
ES2688206T3 (es) 2013-06-17 2018-10-31 Armo Biosciences, Inc. Procedimiento de evaluación de la identidad y la estabilidad de proteínas
US10098929B2 (en) 2013-08-02 2018-10-16 Children's Hospital Medical Center Method of reducing scar formation in healing of dermal wounds by administering interleukin-10 and hyaluronan
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
EP3068425B1 (en) 2013-11-11 2021-01-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
CN107109410B (zh) 2014-08-22 2021-11-02 奥克兰联合服务有限公司 通道调节剂
WO2016060996A2 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
CA2986755A1 (en) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
US10398761B2 (en) 2015-08-25 2019-09-03 Armo Biosciences, Inc. Methods of using combinations of PEG-IL-10 and IL-15 for treating cancers

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007932A1 (en) * 1989-01-20 1990-07-26 The University Of Melbourne Fibrinolysis
WO1991007186A1 (en) * 1989-11-21 1991-05-30 The University Of Melbourne Anti-inflammatory compositions and methods
WO1992011861A1 (en) * 1991-01-10 1992-07-23 Schering Corporation Use of il-4 to enhance the reparative phase of wound healing and repair and to enhance the healing of infected wounds and the wounds of diabetic mammals
WO1993019770A1 (en) * 1992-04-06 1993-10-14 Isis Innovation Limited Compositions for the treatment of acute or chronic inflammation
WO1994027640A1 (en) * 1993-05-27 1994-12-08 The Regents Of The University Of Michigan Method of treatment and prevention of immune complex-induced lung injury

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929442A (en) 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
DE3889479T2 (de) 1987-02-27 1994-12-22 Eastman Kodak Co Mit Nieder-pI-Protein beschichtete Membranstruktur und Verfahren zu ihrer Herstellung und Verwendung.
US5242902A (en) * 1989-09-06 1993-09-07 The Regents Of The University Of California Defensin peptide compositions and methods for their use
JP3616392B2 (ja) 1990-04-11 2005-02-02 ザ・ブリガム・アンド・ウイメンズ・ホスピタル・インコーポレイテッド アクチン結合性化合物の療法的使用
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
AU8647991A (en) 1991-08-26 1993-03-16 State of Oregon Acting by and Through The State of Board of Higher Education on Behalf of The Oregon Health Sciences University, The Keratinocyte-derived conditioned medium as a source of growth factors
GB9206861D0 (en) * 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
FI960353A7 (fi) 1993-07-26 1996-01-26 Schering Corp Ihmisen interleukiini-10:n agonistit ja antagonistit
US5972335A (en) * 1994-03-29 1999-10-26 The Victoria University Of Manchester Wound healing
JPH11501506A (ja) * 1994-12-12 1999-02-09 ベス イスラエル デアコネス メディカル センター キメラ型サイトカインおよびその利用
GB9516012D0 (en) * 1995-08-04 1995-10-04 Univ Manchester Pharmaceutical composition
GB2304045A (en) * 1995-08-04 1997-03-12 Univ Manchester Betaglycan compositions for promoting the healing of wounds and fibrotic diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007932A1 (en) * 1989-01-20 1990-07-26 The University Of Melbourne Fibrinolysis
WO1991007186A1 (en) * 1989-11-21 1991-05-30 The University Of Melbourne Anti-inflammatory compositions and methods
WO1992011861A1 (en) * 1991-01-10 1992-07-23 Schering Corporation Use of il-4 to enhance the reparative phase of wound healing and repair and to enhance the healing of infected wounds and the wounds of diabetic mammals
WO1993019770A1 (en) * 1992-04-06 1993-10-14 Isis Innovation Limited Compositions for the treatment of acute or chronic inflammation
WO1994027640A1 (en) * 1993-05-27 1994-12-08 The Regents Of The University Of Michigan Method of treatment and prevention of immune complex-induced lung injury

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001017558A3 (en) * 1999-09-08 2001-09-27 Schering Corp Novel uses of mammalian ccr6 receptors and related reagents

Also Published As

Publication number Publication date
GB9516287D0 (en) 1995-10-11
US20020128447A1 (en) 2002-09-12
AU6666096A (en) 1997-03-05
JPH11510505A (ja) 1999-09-14
US7052684B2 (en) 2006-05-30
WO1997005894A1 (en) 1997-02-20
EP0871473A1 (en) 1998-10-21
CA2229078C (en) 2010-04-20
ATE229814T1 (de) 2003-01-15
DE69625516D1 (de) 2003-01-30
DE69625516T2 (de) 2003-09-25
US6387364B1 (en) 2002-05-14
DK0871473T3 (da) 2003-04-14
CA2229078A1 (en) 1997-02-20
PT871473E (pt) 2003-03-31
AU719089B2 (en) 2000-05-04
ZA966744B (en) 1998-02-09
EP0871473B1 (en) 2002-12-18
JP4050317B2 (ja) 2008-02-20
ES2187665T3 (es) 2003-06-16

Similar Documents

Publication Publication Date Title
GB2304047A (en) Pharmaceutical compositions containing cytokines
Roberts et al. Physiological actions and clinical applications of transforming growth factor-β (TGF-β)
DE69518156T2 (de) Immunomodulatoren
Piccotti et al. Alloantigen-reactive Th1 development in IL-12-deficient mice
Bessis et al. The type II decoy receptor of IL‐1 inhibits murine collagen‐induced arthritis
DE69830582T2 (de) Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind
DE60208692T2 (de) Interleukin -18 mutantenproteine, deren herstellung und verwendung
DE69119879T2 (de) Epitheliocytenwachstumsbeschleuniger
CA2186269C (en) Wound healing
CA2046900A1 (en) Melanin-concentrating hormones and methods of treatment using same
JP4102437B2 (ja) アクチビンおよびインヒビン刺激因子を含有する医薬組成物
US7220413B2 (en) Pharmaceutical composition containing inhibitors of interferon-γ
JP6005736B2 (ja) Ｉｌ−１２を用いる皮膚損傷の軽減
DE69626050T2 (de) Pharmazeutische zusammensetzung enthaltend interferon-gamma stimulatoren
EP2572724A1 (de) Behandlung von Fibrosen und Lebererkrankungen
US20080031879A1 (en) Pharmaceutical composition containing inhibitors of interferon-gamma
AU747598B2 (en) Pharmaceutical composition containing stimulators of interferon-gamma
WO2000057902A1 (en) Method and pharmaceutical composition for wound healing
US20070053872A1 (en) Treatment of wounds using il-17b
Armour et al. Cellular and molecular pathology of HTS: basis for treatment [corrected][published erratum appears in WOUND REPAIR REGENERATION 2008 Jul-Aug; 16 (4): 582].
HK1024419A (en) Healing of wounds or fibrotic disorders using at least one agent against a growth factor
HK1023516B (en) Pharmaceutical composition containing stimulators of interferon-gamma

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)